Current News

Contact | Print version | PDF version | Send article | RSS feed

Cenix BioScience Expands Usage of Definiens Technology in High-Content Screening

14 Feb 2008 - Definiens and Cenix BioScience GmbH announced that they have expanded their mutual licensing agreement. This strategic decision confirms the heightened commitment of Cenix to the use of the Definiens technology within its organization. Resulting from the findings of an internal review Definiens Cellenger® was reselected as the best available application to support Cenix in the development and implementation of high content (HC) microscopy assays for HT-RNAi studies in cultured human and rodent cells.
 
Dr. Michael Hannus, Group Leader, Cell-based Discovery & Validation at Cenix BioScience, said "After we tested and reviewed the available high content screening software, it became obvious that there is no other solution out there that can support us in the extremely challenging image analysis tasks we perform for our customers."